Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factor-β1

被引:87
作者
Waetzig, GH
Rosenstiel, P
Arlt, A
Till, A
Bräutigam, K
Schäfer, H
Rose-John, S
Seegert, D
Schreiber, S
机构
[1] Schleswig Holstein Univ Med Ctr, Inst Clin Mol Biol, D-24105 Kiel, Germany
[2] Schleswig Holstein Univ Med Ctr, Lab Mol Gastroenterol & Hepatol, Dept Med 1, D-24105 Kiel, Germany
[3] Univ Kiel, Inst Biochem, D-24098 Kiel, Germany
[4] Conaris Res Inst AG, D-24118 Kiel, Germany
关键词
anti-inflammatory agents; autoimmune diseases; inflammation; mitogen-activated protein kinases; signal transduction;
D O I
10.1096/fj.04-2073fje
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) plays a central role in inflammatory disorders. Transmembrane TNF-alpha and its two receptors are cleaved by the proteinase TNF-alpha converting enzyme (TACE), resulting in appreciable serum levels of soluble TNF-alpha and soluble TNF-alpha receptors (sTNFR1 and -2). The only known functions of sTNFR1 are to antagonize and buffer circulating TNF-alpha. Here, we present evidence that sTNFR1 exerts immunoregulatory functions by induction of apoptosis in monocytes through reverse signaling via transmembrane TNF-alpha. sTNFR1-induced apoptosis is independent of death receptor pathways but depends on autocrine transforming growth factor (TGF)-beta1 signaling through the mitogen-activated protein kinase p38alpha. This novel mechanism has implications for understanding the physiological role of sTNFR1 and for TNF-alpha-blocking therapies of autoimmune diseases.
引用
收藏
页码:91 / +
页数:19
相关论文
共 63 条
  • [21] TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways
    Hsu, HL
    Shu, HB
    Pan, MG
    Goeddel, DV
    [J]. CELL, 1996, 84 (02) : 299 - 308
  • [22] SOLUBLE TNF RECEPTORS (TNF-SR(55) AND TNF-SR(75)) IN LUNG ALLOGRAFT RECIPIENTS DISPLAYING CYTOMEGALOVIRUS PNEUMONITIS
    HUMBERT, M
    ROUXLOMBARD, P
    CERRINA, J
    MAGNAN, A
    SIMONNEAU, C
    DARTEVELLE, P
    GALANAUD, P
    DAYER, JM
    EMILIE, D
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (06) : 1681 - 1685
  • [23] Ina K, 1999, J IMMUNOL, V163, P1081
  • [24] ACTIVATION OF HUMAN-BLOOD MONOCYTES BY ADHERENCE TO TISSUE-CULTURE PLASTIC SURFACES
    KELLEY, JL
    ROZEK, MM
    SUENRAM, CA
    SCHWARTZ, CJ
    [J]. EXPERIMENTAL AND MOLECULAR PATHOLOGY, 1987, 46 (03) : 266 - 278
  • [25] LPS resistance in monocytic cells caused by reverse signaling through transmembrane TNF (mTNF) is mediated by the MAPK/ERK pathway
    Kirchner, S
    Boldt, S
    Kolch, W
    Haffner, S
    Kazak, S
    Janosch, P
    Holler, E
    Andreesen, R
    Eissner, G
    [J]. JOURNAL OF LEUKOCYTE BIOLOGY, 2004, 75 (02) : 324 - 331
  • [26] A 2ND TUMOR-NECROSIS-FACTOR RECEPTOR GENE-PRODUCT CAN SHED A NATURALLY-OCCURRING TUMOR-NECROSIS-FACTOR INHIBITOR
    KOHNO, T
    BREWER, MT
    BAKER, SL
    SCHWARTZ, PE
    KING, MW
    HALE, KK
    SQUIRES, CH
    THOMPSON, RC
    VANNICE, JL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (21) : 8331 - 8335
  • [27] Krause Stefan W., 1996, Immunobiology, V196, P522
  • [28] EVIDENCE THAT BCL-2 REPRESSES APOPTOSIS BY REGULATING ENDOPLASMIC RETICULUM-ASSOCIATED CA2+ FLUXES
    LAM, M
    DUBYAK, G
    CHEN, L
    NUNEZ, G
    MIESFELD, RL
    DISTELHORST, CW
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (14) : 6569 - 6573
  • [29] Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway
    Lügering, A
    Schmidt, M
    Lügering, N
    Pauels, HG
    Domschke, W
    Kucharzik, T
    [J]. GASTROENTEROLOGY, 2001, 121 (05) : 1145 - 1157
  • [30] Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-α
    Mitoma, H
    Horiuchi, T
    Tsukamoto, H
    [J]. GASTROENTEROLOGY, 2004, 126 (03) : 934 - 935